These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25231401)

  • 1. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
    Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
    Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
    Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
    Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
    Ma L; Lai D; Liu T; Cheng W; Guo L
    Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species.
    Zhou J; Li P; Xue X; He S; Kuang Y; Zhao H; Chen S; Zhi Q; Guo X
    Toxicol Lett; 2013 Oct; 222(2):139-45. PubMed ID: 23916687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
    Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
    Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
    Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
    Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
    Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
    Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
    Frankel A; Buckman R; Kerbel RS
    Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer.
    Yang X; Zheng F; Xing H; Gao Q; Wei W; Lu Y; Wang S; Zhou J; Hu W; Ma D
    J Cancer Res Clin Oncol; 2004 Jul; 130(7):423-8. PubMed ID: 15156398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
    Qi C; Zhang QH; Li JX
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
    Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
    Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.
    Hirst J; Pathak HB; Hyter S; Pessetto ZY; Ly T; Graw S; Koestler DC; Krieg AJ; Roby KF; Godwin AK
    Cancer Res; 2018 Aug; 78(15):4370-4385. PubMed ID: 29891506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids.
    Makhija S; Taylor DD; Gibb RK; Gerçel-Taylor C
    Int J Oncol; 1999 Mar; 14(3):515-21. PubMed ID: 10024685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel.
    Casagrande N; Borghese C; Agostini F; Durante C; Mazzucato M; Colombatti A; Aldinucci D
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LGR5 is required for the maintenance of spheroid-derived colon cancer stem cells.
    Chen X; Wei B; Han X; Zheng Z; Huang J; Liu J; Huang Y; Wei H
    Int J Mol Med; 2014 Jul; 34(1):35-42. PubMed ID: 24789370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Frankel A; Man S; Elliott P; Adams J; Kerbel RS
    Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.